(197 days)
No
The description details standard clinical chemistry and ISE methods, and there is no mention of AI, ML, or related technologies.
No
The device is an in vitro diagnostic (IVD) clinical chemistry system used for quantitative measurements of certain analytes in patient samples, which aid in diagnosis and treatment, but the device itself does not directly provide therapy.
Yes
The "Intended Use / Indications for Use" section explicitly states that the system is "intended for in vitro diagnostic use in the quantitative measurement of general chemistry assays for clinical use," and that measurements of sodium, potassium, chloride, and glucose are "used in the diagnosis and treatment of diseases."
No
The device description explicitly states that the system consists of two major components: a chemistry instrument and an integrated Panel PC. The instrument performs physical measurements on samples, indicating the presence of hardware beyond just software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Explicit Statement: The "Intended Use / Indications for Use" section clearly states: "The ACE Axcel Clinical Chemistry System is an automated, discrete, bench-top, random access analyzer that is intended for in vitro diagnostic use..." and "For in vitro diagnostic use only." This is the most direct indicator.
- Nature of the Tests: The device performs quantitative measurements of general chemistry assays (sodium, potassium, chloride, glucose) in biological samples (serum). These types of tests are inherently in vitro diagnostics, as they are performed outside of the living body to provide information for diagnosis and treatment.
- Clinical Use: The intended use specifies "for clinical use in physician office laboratories or clinical laboratories," which aligns with the typical use of IVD devices in healthcare settings.
- Diagnostic Purpose: The descriptions of the individual tests (sodium, potassium, chloride, glucose) explicitly state their use in the "diagnosis and treatment of diseases" and "monitoring electrolyte balance." This confirms the diagnostic purpose of the measurements.
N/A
Intended Use / Indications for Use
The ACE Axcel Clinical Chemistry System is an automated, discrete, bench-top, random access analyzer that is intended for in vitro diagnostic use in the quantitative determination of constituents in blood and other fluids.
The ACE Glucose Reagent is intended for the quantitative determination of glucose concentration in serum using the ACE Axcel Clinical Chemistry System. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.
The ACE Axcel Clinical System includes an Ion Selective Electrode (ISE) module for the measurement of sodium, potassium and chloride in undiluted serum. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only. Sodium measurements are used in the diagnosis and treatment of diseases involving electrolyte imbalance Potassium measurements are used to monitor electrolyte balance and in the diagnosis and treatment of diseases conditions characterized by low or high blood potassium levels. Chloride measurements are used in the diagnosis and treatment of electrolyte and metabolic disorders such as cystic fibrosis and diabetic acidosis.
Product codes
JJE, CFR, JGS, CEM, CGZ
Device Description
The ACE Axcel Clinical Chemistry System consists of two major components, the chemistry instrument and an integrated Panel PC. The instrument accepts the physical patient samples, performs the appropriate optical or potentiometric measurements on those samples and communicates that data to an integral Panel PC. The Panel PC uses keyboard or touch screen input to manually enter a variety of data, control and accept data from the instrument, manage and maintain system information and generate reports relative to patient status and instrument performance. The Panel PC also allows remote download of patient requisitions and upload of patient results via a standard interface.
In the ACE Glucose Reagent assay, glucose in serum reacts with adenosine triphosphate in the presence of hexokinase and magnesium with the formation of glucose-6-phosphate and adenosine diphosphate. Glucose-6-phosphate dehydrogenase catalyzes the oxidation of glucose-6-phosphate with NAD+ to form 6-phosphogluconate and NADH. NADH absorbs strongly at 340 nm, whereas NAD+ does not. The total amount of NADH formed is proportional to the concentration of glucose in the sample. The increase in absorbance is measured bichromatically at 340 nm/378 nm.
The ACE Ion Selective Electrode (ISE) Module is used with ACE CAL A and CAL B Calibration Solutions in the performance of a two-point calibration in order to measure concentrations of sodium, potassium and chloride in undiluted serum. The ISE module uses a potentiometric method to simultaneously measure sodium, potassium and chloride in undiluted serum. Each electrode uses an ion-specific membrane to measure the difference in ionic concentration between an inner electrolyte solution and the sample. This difference causes an electro-chemical potential to form on the membrane of the active electrode. The connection of the amplifier and ground (reference electrode) to the ion selective electrode forms the measuring system. The two-point calibration with CAL A and CAL B with precisely known ion concentrations (two-point calibration) and the measured voltage difference of the sample and CAL A are used to determine the ion concentration in the sample.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
clinical laboratories or physician office laboratories
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Performance data for the Alfa Wassermann ACE Reagents run on the Alfa Wassermann ACE Axcel Clinical Chemistry System included precision, accuracy, and detection limit data.
ACE Glucose Reagent:
Precision: In testing conducted at four glucose levels for 22 days, the within-run CV ranged from 1.0 to 1.4%, and total CV ranged from 1.0 to 1.9%. In precision studies at three separate Physician Office Laboratory (POL) sites over 5 days, the within-run CV ranged from 0.3 to 2.2% and total CV ranged from 0.5 to 2.2%.
Accuracy: In the correlation study, 122 samples with glucose values ranging from 6 to 729 mg/dL were assayed on the Alfa Wassermann ACE Axcel Clinical Chemistry System (y) and the Alfa Wassermann ACE Clinical Chemistry System (x). Least squares regression analysis yielded a correlation coefficient of 0.9998, a standard error estimate of 3.1, a confidence interval slope of 1.001 to 1.009, and a confidence interval intercept of -1.5 to 0.1. In patient correlation studies at three separate POL sites, using the Alfa Wassermann ACE Axcel Clinical Chemistry System (y) and the Alfa Wassermann ACE Clinical Chemistry System (x), least-squares regression analysis yielded correlation coefficients of 0.9992 to 0.9998, standard error estimates of 3.6 to 7.0, confidence interval slopes of 0.972 to 1.021, and a confidence interval intercepts of -3.0 to 4.1.
Detection limit: The detection limit was 3.1 mg/dL.
ACE Axcel Sodium ISE:
Precision: In testing conducted at four sodium levels for 21 days, the within-run CV ranged from 0.4 to 1.0%, and total CV ranged from 0.8 to 1.4%. In precision studies at three separate Physician Office Laboratory (POL) sites over 5 days, the within-run CV ranged from 0.6 to 1.0% and total CV ranged from 0.8 to 1.4%.
Accuracy: In the correlation study, 113 samples with sodium values ranging from 45.1 to 194.0 mmol/L were assayed on the Alfa Wassermann ACE Axcel Clinical Chemistry System (y) and the Alfa Wassermann ACE Clinical Chemistry System (x). Least squares regression analysis yielded a correlation coefficient of 0.9963, a standard error estimate of 1.65, a confidence interval slope of 0.992 to 1.024, and a confidence interval intercept of -3.60 to 0.92. In patient correlation studies at three separate POL sites, using the Alfa Wassermann ACE Axcel Clinical Chemistry System (y) and the Alfa Wassermann ACE Clinical Chemistry System (x), least-squares regression analysis yielded correlation coefficients of 0.9917 to 0.9995, standard error estimates of 0.74 to 3.07, confidence interval slopes of 0.989 to 1.067, and a confidence interval intercepts of -8.85 to 2.30.
ACE Axcel Potassium ISE:
Precision: In testing conducted at four potassium levels for 21 days, the within-run CV ranged from 0.6 to 3.5%, and total CV ranged from 1.3 to 3.5%. In precision studies at three separate Physician Office Laboratory (POL) sites over 5 days, the within-run CV ranged from 1.0 to 1.6% and total CV ranged from 1.1 to 1.6%.
Accuracy: In the correlation study, 115 samples with potassium values ranging from 1.57 to 14.20 mmol/L were assayed on the Alfa Wassermann ACE Axcel Clinical Chemistry System (y) and the Alfa Wassermann ACE Clinical Chemistry System (x). Least squares regression analysis yielded a correlation coefficient of 0.9974, a standard error estimate of 0.146, a confidence interval slope of 0.989 to 1.015, and a confidence interval intercept of -0.050 to 0.095. In patient correlation studies at three separate POL sites, using the Alfa Wassermann ACE Axcel Clinical Chemistry System (y) and the Alfa Wassermann ACE Clinical Chemistry System (x), least-squares regression analysis yielded correlation coefficients of 0.9973 to 0.9996, standard error estimates of 0.064 to 0.182, confidence interval slopes of 0.960 to 1.035, and a confidence interval intercepts of -0.194 to 0.216.
ACE Axcel Chloride ISE:
Precision: In testing conducted at four chloride levels for 21 days, the within-run CV ranged from 0.5 to 1.0%, and total CV ranged from 1.1 to 1.5%. In precision studies at three separate Physician Office Laboratory (POL) sites over 5 days, the within-run CV ranged from 0.9 to 1.5% and total CV ranged from 1.1 to 2.6%.
Accuracy: In the correlation study, 111 samples with chloride values ranging from 63.4 to 176.0 mmol/L were assayed on the Alfa Wassermann ACE Axcel Clinical Chemistry System (y) and the Alfa Wassermann ACE Clinical Chemistry System (x). Least squares regression analysis yielded a correlation coefficient of 0.9855, a standard error estimate of 2.05, a confidence interval slope of 0.939 to 1.002, and a confidence interval intercept of -1.07 to 5.63. In patient correlation studies at three separate POL sites, using the Alfa Wassermann ACE Axcel Clinical Chemistry System (y) and the Alfa Wassermann ACE Clinical Chemistry System (x), least-squares regression analysis yielded correlation coefficients of 0.9885 to 0.9996, standard error estimates of 0.55 to 3.05, confidence interval slopes of 0.976 to 1.088, and a confidence interval intercepts of -8.16 to 2.22.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Alfa Wassermann ACE plus ISE/Clinical Chemistry System ACE Reagents (K931786)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.2160 Discrete photometric chemistry analyzer for clinical use.
(a)
Identification. A discrete photometric chemistry analyzer for clinical use is a device intended to duplicate manual analytical procedures by performing automatically various steps such as pipetting, preparing filtrates, heating, and measuring color intensity. This device is intended for use in conjunction with certain materials to measure a variety of analytes. Different models of the device incorporate various instrumentation such as micro analysis apparatus, double beam, single, or dual channel photometers, and bichromatic 2-wavelength photometers. Some models of the device may include reagent-containing components that may also serve as reaction units.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
0
Alfa Wassermann Diagnostic Technologies, LLC
MAY 1 7 2012
510(k) Submission ACE Axcel Clinical Chemistry System ACE Reagents
13253
510(k) SUMMARY
Alfa Wassermann Diagnostic Technologies, LLC 510(k) Owner: 4 Henderson Drive West Caldwell, NJ 07006 Contact: Hyman Katz, Ph.D. Phone: 973-852-0158 Fax: 973-852-0237 Date Summary November 1, 2011 Prepared: Trade Name: ACE Axcel Clinical Chemistry System Device: Class 1 Classification: Common/Classification Name: Analyzer, Chemistry (Photometric, Discrete), For Clinical Use (21 C.F.R. § 862.2610) Product Code JJE ACE Glucose Reagent Trade Name: Classification: Class 2 Common/Classification Name: Hexokinase, Glucose (21 C.F.R. & 862.1345) Product Code CFR ACE Ion Selective Electrode (ISE) Trade Name: Module Classification: Class 2 Common/Classification Name: Electrode, Ion Specific, Sodium, Potassium, Chloride (21 C.F.R. § 862.1665, 862.1600, 862.1170) Product Codes JGS, CEM, CGZ Predicate Manufacturer for analyzer/reagent system predicate: Devices: Alfa Wassermann ACE plus ISE/Clinical Chemistry System ACE Reagents (K931786)
1
.
ﺮ ﺍﻟﻤﺮﺍﺟﻊ
| Device | The ACE Axcel Clinical Chemistry System consists of two major |
|---|---|
| Descriptions: | components, the chemistry instrument and an integrated Panel PC. The |
| instrument accepts the physical patient samples, performs the | |
| appropriate optical or potentiometric measurements on those samples | |
| and communicates that data to an integral Panel PC. The Panel PC uses | |
| keyboard or touch screen input to manually enter a variety of data, | |
| control and accept data from the instrument, manage and maintain | |
| system information and generate reports relative to patient status and | |
| instrument performance. The Panel PC also allows remote download of | |
| patient requisitions and upload of patient results via a standard | |
| interface. | |
| In the ACE Glucose Reagent assay, glucose in serum reacts with | |
| adenosine triphosphate in the presence of hexokinase and magnesium | |
| with the formation of glucose-6-phosphate and adenosine diphosphate. | |
| Glucose-6-phosphate dehydrogenase catalyzes the oxidation of | |
| glucose-6-phosphate with NAD+ to form 6-phosphogluconate and | |
| NADH. NADH absorbs strongly at 340 nm, whereas NAD+ does not. | |
| The total amount of NADH formed is proportional to the concentration | |
| of glucose in the sample. The increase in absorbance is measured | |
| bichromatically at 340 nm/378 nm. | |
| The ACE Ion Selective Electrode (ISE) Module is used with ACE CAL | |
| A and CAL B Calibration Solutions in the performance of a two-point | |
| calibration in order to measure concentrations of sodium, potassium | |
| and chloride in undiluted serum. The ISE module uses a potentiometric | |
| method to simultaneously measure sodium, potassium and chloride in | |
| undiluted serum. Each electrode uses an ion-specific membrane to | |
| measure the difference in ionic concentration between an inner | |
| electrolyte solution and the sample. This difference causes an electro- | |
| chemical potential to form on the membrane of the active electrode. | |
| The connection of the amplifier and ground (reference electrode) to the | |
| ion selective electrode forms the measuring system. The two-point | |
| calibration with CAL A and CAL B with precisely known ion | |
| concentrations (two-point calibration) and the measured voltage | |
| difference of the sample and CAL A are used to determine the ion | |
| concentration in the sample. | |
| Intended Use: | Indications for Use: |
| The ACE Axcel Clinical Chemistry System is an automated, discrete, | |
| bench-top, random access analyzer that is intended for in vitro | |
| diagnostic use in the quantitative determination of constituents in blood | |
| and other fluids. | |
| The ACE Glucose Reagent is intended for the quantitative | |
| determination of glucose concentration in serum using the ACE Axcel | |
| Clinical Chemistry System. Glucose measurements are used in the | |
| diagnosis and treatment of carbohydrate metabolism disorders | |
| including diabetes mellitus, neonatal hypoglycemia, and idiopathic | |
| hypoglycemia, and of pancreatic islet cell carcinoma. This test is | |
| intended for use in clinical laboratories or physician office laboratories. | |
| For in vitro diagnostic use only. | |
| The ACE Axcel Clinical System includes an Ion Selective Electrode | |
| (ISE) module for the measurement of sodium, potassium and chloride | |
| in undiluted serum. This test is intended for use in clinical laboratories | |
| or physician office laboratories. For in vitro diagnostic use only. | |
| Sodium measurements are used in the diagnosis and treatment | |
| of diseases involving electrolyte imbalance Potassium measurements are used to monitor electrolyte | |
| balance and in the diagnosis and treatment of diseases | |
| conditions characterized by low or high blood potassium | |
| levels. Chloride measurements are used in the diagnosis and treatment | |
| of electrolyte and metabolic disorders such as cystic | |
| fibrosis and diabetic acidosis. | |
| Technological | |
| Characteristics: | The following is a description of the major features of the ACE Axcel |
| Clinical Chemistry System: System throughput is approximately 160 test results per hour for | |
| routine, single reagent chemistries. System throughput will be | |
| higher when the test workload includes ISE's. The instrument has a capacity of 40 reagent containers on board. | |
| A reagent cooling system maintains the reagents at 12°C during | |
| instrument operation. Reagent containers are identified by computer coded labels to | |
| simplify system operation. All reagents in the system must | |
| include an identification label on the container. Sample and reagent sensing notify the operator of a depleted | |
| condition during operation. The system performs analysis at a reaction temperature of 37°C. An electrolyte subsystem capable of measuring sodium, | |
| potassium and chloride concentrations is included. Primary draw tubes may be introduced one at a time into the | |
| system for closed tube sampling. Positive tube identification can | |
| be achieved with an optional barcode scanner. An aliquot volume | |
| sufficient for all tests ordered is transferred and stored and the | |
| closed tube is returned to the user. | |
| • Sample cups are introduced to the system one at a time or by | |
| sample ring segment. | |
| • Disposable cuvettes are loaded in bulk and then automatically | |
| injected as needed by a cuvette hopper system. The ACE Axcel | |
| clinical chemistry optical system is capable of monitoring a | |
| maximum of 48 cuvettes at one time. | |
| • The absorbance optical system is capable of absorbance | |
| measurements in a linear range of 0.0 to 2.0 absorbance units (at | |
| 0.67 cm pathlength). Sixteen wavelengths are measured | |
| simultaneously using a photodiode array. | |
| The ACE Glucose Reagent consists of a single reagent bottle. The | |
| reagent contains nicotinamide adenine dinucleotide (NAD+), adenosine | |
| 5'-triphosphate (ATP), magnesium, hexokinase and glucose-6- | |
| phosphate dehydrogenase. | |
| The ACE Ion Selective Electrode (ISE) Module uses a potentiometric | |
| method to simultaneously measure sodium, potassium and chloride in | |
| undiluted serum. Each electrode uses an ion-specific membrane to | |
| measure the difference in ionic concentration between an inner | |
| electrolyte solution and the sample. | |
| Performance | |
| Data: | Performance data for the Alfa Wassermann ACE Reagents run on the |
| Alfa Wassermann ACE Axcel Clinical Chemistry System included | |
| precision, accuracy, and detection limit data. | |
| ACE Glucose Reagent | |
| Precision: In testing conducted at four glucose levels for 22 days, the | |
| within-run CV ranged from 1.0 to 1.4%, and total CV ranged from 1.0 | |
| to 1.9%. In precision studies at three separate Physician Office | |
| Laboratory (POL) sites over 5 days, the within-run CV ranged from 0.3 | |
| to 2.2% and total CV ranged from 0.5 to 2.2%. | |
| Accuracy: In the correlation study, 122 samples with glucose values | |
| ranging from 6 to 729 mg/dL were assayed on the Alfa Wassermann | |
| ACE Axcel Clinical Chemistry System (y) and the Alfa Wassermann | |
| ACE Clinical Chemistry System (x). Least squares regression analysis | |
| yielded a correlation coefficient of 0.9998, a standard error estimate of | |
| 3.1, a confidence interval slope of 1.001 to 1.009, and a confidence | |
| interval intercept of -1.5 to 0.1. In patient correlation studies at three | |
| separate POL sites, using the Alfa Wassermann ACE Axcel Clinical | |
| Chemistry System (y) and the Alfa Wassermann ACE Clinical | |
| Chemistry System (x), least-squares regression analysis yielded | |
| correlation coefficients of 0.9992 to 0.9998, standard error estimates of | |
| 3.6 to 7.0, confidence interval slopes of 0.972 to 1.021, and a | |
| confidence interval intercepts of -3.0 to 4.1. | |
| Detection limit: The detection limit was 3.1 mg/dL. |
.
2
·
·
:
·
. .
·
·
.
3
:
.
.
.
·
·
・
4
ACE Axcel Sodium ISE
Precision: In testing conducted at four sodium levels for 21 days, the within-run CV ranged from 0.4 to 1.0%, and total CV ranged from 0.8 to 1.4%. In precision studies at three separate Physician Office Laboratory (POL) sites over 5 days, the within-run CV ranged from 0.6 to 1.0% and total CV ranged from 0.8 to 1.4%.
Accuracy: In the correlation study, 113 samples with sodium values ranging from 45.1 to194.0 mmol/L were assayed on the Alfa Wassermann ACE Axcel Clinical Chemistry System (y) and the Alfa Wassermann ACE Clinical Chemistry System (x). Least squares regression analysis vielded a correlation coefficient of 0.9963, a standard error estimate of 1.65, a confidence interval slope of 0.992 to 1.024, and a confidence interval intercept of -3.60 to 0.92. In patient correlation studies at three separate POL sites, using the Alfa Wassermann ACE Axcel Clinical Chemistry System (y) and the Alfa Wassermann ACE Clinical Chemistry System (x), least-squares regression analysis yielded correlation coefficients of 0.9917 to 0.9995, standard error estimates of 0.74 to 3.07, confidence interval slopes of 0.989 to 1.067, and a confidence interval intercepts of -8.85 to 2.30.
ACE Axcel Potassium ISE
Precision: In testing conducted at four potassium levels for 21 days, the within-run CV ranged from 0.6 to 3.5%, and total CV ranged from 1.3 to 3.5%. In precision studies at three separate Physician Office Laboratory (POL) sites over 5 days, the within-run CV ranged from 1.0 to 1.6% and total CV ranged from 1.1 to 1.6%.
Accuracy: In the correlation study, 115 samples with potassium values ranging from 1.57 to 14.20 mmol/L were assayed on the Alfa Wassermann ACE Axcel Clinical Chemistry System (y) and the Alfa Wassermann ACE Clinical Chemistry System (x). Least squares regression analysis vielded a correlation coefficient of 0.9974, a standard error estimate of 0.146, a confidence interval slope of 0.989 to 1.015, and a confidence interval intercept of -0.050 to 0.095. In patient correlation studies at three separate POL sites, using the Alfa Wassermann ACE Axcel Clinical Chemistry System (y) and the Alfa Wassermann ACE Clinical Chemistry System (x), least-squares regression analysis vielded correlation coefficients of 0.9973 to 0.9996, standard error estimates of 0.064 to 0.182, confidence interval slopes of 0.960 to 1.035, and a confidence interval intercepts of -0.194 to 0.216.
5
.
.
:
:
·
:
:
| Conclusions: | ACE Axcel Chloride ISE
Precision: In testing conducted at four chloride levels for 21 days, the
within-run CV ranged from 0.5 to 1.0%, and total CV ranged from 1.1
to 1.5%. In precision studies at three separate Physician Office
Laboratory (POL) sites over 5 days, the within-run CV ranged from 0.9
to 1.5% and total CV ranged from 1.1 to 2.6%.
Accuracy: In the correlation study, 111 samples with chloride values
ranging from 63.4 to 176.0 mmol/L were assayed on the Alfa
Wassermann ACE Axcel Clinical Chemistry System (y) and the Alfa
Wassermann ACE Clinical Chemistry System (x). Least squares
regression analysis yielded a correlation coefficient of 0.9855, a
standard error estimate of 2.05, a confidence interval slope of 0.939 to
1.002, and a confidence interval intercept of -1.07 to 5.63. In patient
correlation studies at three separate POL sites, using the Alfa
Wassermann ACE Axcel Clinical Chemistry System (y) and the Alfa
Wassermann ACE Clinical Chemistry System (x), least-squares
regression analysis yielded correlation coefficients of 0.9885 to 0.9996,
standard error estimates of 0.55 to 3.05, confidence interval slopes of
0.976 to 1.088, and a confidence interval intercepts of -8.16 to 2.22. |
|--------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | Based on the foregoing data, the device is safe and effective. These
data also indicate substantial equivalence to the predicate device. |
·
:
:
:
·
.
6
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/6/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle or bird-like figure with three curved lines representing its body and wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" is arranged in a circular fashion around the emblem.
Food and Drug Administration
10903 New Hampshire Avenue Silver Spring, MD 20993
ALFA WASSERMANN Diagnostic Technologies, Inc c/o Hyman Katz 4 Henderson Drive West Caldwell, NJ 07006
MAY 1 7 2012
K113253 Re:
.
Trade Name: ACE Axcel Clinical Chemistry System, ACE Ion Selective Electrode (ISE) Module, ACE Glucose Reagent
Regulation Number: 21 CFR §862.1345
Regulation Name: Glucose test system
Regulatory Class: Class II
Product Codes: CFR, JGS, CEM, CGZ, JJE
Dated: April 12, 2012
Received: April 13, 2012
Dear Dr. Katz:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
7
Page 2
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/Medical
Devices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance...
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm
Sincerely yours,
signature
Counney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
8
Indications for Use
510(k) Number: K113253
Device Name: ACE Axcel Clinical Chemistry System, ACE Ion Selective Electrode (ISE) Module, ACE Glucose Reagent
Indications for Use:
The ACE Axcel Clinical Chemistry System is an automated, discrete, bench-top, random access analyzer that is intended for in vitro diagnostic use in the quantitative measurement of general chemistry assays for clinical use in physician office laboratories or clinical laboratories.
The ACE Axcel Clinical System includes an Ion Selective Electrode (ISE) module for the measurement of sodium, potassium and chloride in serum. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.
- Sodium measurements are used in the diagnosis and treatment of . diseases involving electrolyte imbalance
- Potassium measurements are used to monitor electrolyte balance . and in the diagnosis and treatment of diseases conditions characterized by low or high blood potassium levels.
- Chloride measurements are used in the diagnosis and treatment of electrolyte and metabolic disorders such as cystic fibrosis and diabetic acidosis.
The ACE Glucose Reagent is intended for the quantitative determination of glucose concentration in serum using the ACE Axcel Clinical Chemistry System. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.
Prescription Use X (21 CFR Part 801 Subpart D) AND/OR
Over-The-Counter Use. (21 CFR Part 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In vitro Diagnostic Devices (OIVD)
Ruta chulen
Division Sign-Off Office of In vitro Diagnostic Device Evaluation and Safety
k 1 13 253 510(k)